An Open-label, Dose-escalating Clinical Study to Evaluate the Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation (EP) in an Add-on Therapy With Entecavir in Chronic Hepatitis B Patients
Latest Information Update: 25 Jun 2013
At a glance
- Drugs GX 110 (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Adverse reactions
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2012 New trial record